NLS AlzeCure

AlzeCure Pharma has announced the outcome of the rights issue with preferential rights for the shareholders that ended on March 22, 2022. The subscription breakdown show that approximately 59.4 percent was subscribed with and without the exercise of subscription rights. Consequently underwriters of the Rights Issue will be allocated approximately 20.8 percent of the Rights […]

AlzeCure Pharma is developing a novel clinical drug candidate for peripheral neuropathic pain, which is based on the seminal discoveries of TRPV1 by Professor Julius, and for which he is awarded the Nobel Prize in Medicine 2021. David Julius has together with Ardem Patapoutian recently been awarded the 2021 Nobel Prize in Physiology or Medicine. […]

AlzeCure Pharma has received approval from the regulatory authorities in Sweden to begin the next clinical phase I study (multiple ascending dose, MAD) with the candidate drug ACD856 focused on Alzheimer’s disease. “This is a statement of strength that shows that AlzeCure continues to deliver according to plan,” says Martin Jönsson, CEO of AlzeCure Pharma. […]

AlzeCure Pharma has presented new study results at at the Alzheimer’s Association International Conference (AAIC) 2021. The new results demonstrate how their clinical candidate drug ACD856 for Alzheimer’s disease binds to neurotrophin receptors, so-called Trk receptors. The studies show that ACD856 affects important neurotransmitters in areas of the brain that play an important role in cognition […]

AlzeCure announced that data from its TrkA and TrkB positive allosteric modulator program for Alzheimer’s disease will be presented at the 17th International Conference on Alzheimer’s Drug Discovery in Jersey City, NJ, USA. The oral presentation will include preclinical in vivo Proof-of-Principle data of AC-1122, an approved drug that is undergoing repurposing for the treatment […]